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Background
EnAd is a potent, chimeric Ad11p/Ad3 adenovirus with
selective oncolytic activity against a range of epithelial
cancer cells. Ongoing clinical studies have shown that i.
v. dosed EnAd infects and selectively replicates in tumor
cells, producing detectable levels of viral protein, often
with an associated high frequency of intra-tumoral
CD8+ cells. These data indicate that transgene-encoded
proteins will also be effectively produced within tumors
using an “armed” EnAd virus.
Methods
We are therefore developing EnAd viruses that are armed
for selective delivery of immunotherapeutics to tumors
following systemic dosing. EnAd is highly human-tumor
selective and does not replicate, produce infectious pro-
geny or express endogenously regulated transgenes in
non-human cells. Preclinical evaluation of immuno-
modulatory activities of armed viruses is therefore a
major challenge and requires application of multiple
approaches that can collectively provide informative data.
To evaluate local immunomodulatory effects of EnAd
viruses we have been working with the following sys-
tems:
1. In vitro co-cultures of primary human immune
cells and tumor cells
2. In vivo studies in immunocompetent mice using
i.t. dosing of mouse CT26 tumors with armed EnAd
variants, where transgene expression is driven by a
CMV promoter
3. In vivo studies with human tumor xenografts in
immunodeficient mice with a reconstituted immune
system, where armed EnAd viruses can be dosed sys-
temically to selectively infect tumors and modulate
local immune responses - in the context of viral
infection and tumor cell lysis
Results
Using these approaches we have shown that EnAd treat-
ment results in sustained local production of transgenes
in tumors and can also lead to maturation and activa-
tion of dendritic cells, upregulating CD80, CD86 and
MHC class II following the oncolytic release of virus
particles. This innate stimulation results in enhanced
T cell activation as evidenced by increased tumor anti-
gen-specific T cell responses and CD69 upregulation,
IFN-g & IL-2 secretion. For example, using a virus
encoding the tumor associated antigen NY-ESO-1 (NG-
217) injected into CT26 tumours we demonstrated the
induction of antigen-specific T cell ELISPOT responses
to both encoded NY-ESO-1 epitopes and CT26 tumor
antigens. This correlated with retardation in tumor
growth in NG-217 treated animals. Thus transgene
expression and the presence of viral particles in the
tumor can drive active anti-tumor T cell responses.
Conclusions
These systems are now being used to evaluate efficacy
and mechanism of action of immunotherapeutic agents,
such as immune activators and checkpoint inhibitors,
produced locally within tumor tissues following delivery
of armed EnAd viruses.
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